newswise: Pox Vaccines Extend Survival for Patients with Melanoma, Ovarian Cancer in U.S., German Studies

Pox Vaccines Extend Survival for Patients with Melanoma, Ovarian Cancer in U.S., German Studies

Released: 3/26/2012 3:05 PM EDT
Source: Roswell Park Cancer Institute

 

Newswise — BUFFALO, NY — An immunotherapy regimen incorporating poxviruses and targeting a particular tumor antigen, NY-ESO-1, has shown promise in treating two types of cancers. Kunle Odunsi, MD, PhD, Chair of the Department of Gynecologic Oncology and Director of the Center for Immunotherapy at Roswell Park Cancer Institute (RPCI), Elke Jäger, MD, Head of the Department of Oncology and Hematology at Krankenhaus Nordwest, Frankfurt, and colleagues today published results from two studies testing this approach in PNAS, the Proceedings of the National Academy of Sciences of the United States of America...........

Tumor-reactive CD8+ T-cell responses after vaccination with NY-ESO-1 peptide, CpG 7909 and Montanide ISA-51: association with survival.